Helicobacter pylori (H. pylori): Should it be tested and eradicated? A look at testing methods and the relationship with gastric cancer.
Helicobacter pylori (H. pylori) is a bacterium that colonizes the stomach, a major cause of chronic gastritis and gastric/duodenal ulcers, and is classified as a Group 1 (definite) carcinogen by the WHO IARC—most gastric cancers are associated with it. However, most infected individuals are asymptomatic, and not everyone needs testing or treatment. Common tests include urea breath test, stool antigen, and endoscopic biopsy; blood antibodies only indicate 'past exposure' and cannot confirm current infection or eradication. Studies show that eradication reduces (but does not eliminate) gastric cancer risk; the large-scale eradication program in Matsu, Taiwan, is a well-known example. Whether to test and treat should be determined by a physician based on symptoms and risk assessment, following the latest HPA announcements; eradication therapy requires a prescription—do not self-medicate. This page provides neutral information, not medical advice.
What is Helicobacter pylori? Its relationship with gastric cancer and peptic ulcers
It is a bacterium that can survive in the acidic stomach, and only long-term chronic inflammation may cause disease:
- It is a major cause of chronic gastritis and peptic ulcers (gastric ulcer, duodenal ulcer)
- The WHO IARC classified it as a Group 1 (definite) carcinogen in 1994, and it is a major risk factor for gastric adenocarcinoma and gastric MALT lymphoma; most gastric cancers are associated with infection
- Key point: Most infected individuals are asymptomatic long-term; infection does not mean they will definitely get gastric cancer, but it is a manageable risk factor
How common is it in Taiwan? How is it transmitted?
H. pylori is common worldwide, and Taiwan is no exception:
- Most infections occur in childhood, mainly through fecal-oral and oral-oral routes (e.g., shared eating, hygiene conditions, household clustering)
- The prevalence in Taiwanese adults is around 30%, higher in some high-risk areas (e.g., certain indigenous townships) — figures vary by source and year; refer to the latest data from the Health Promotion Administration
- Most infected individuals are asymptomatic, so infection is often only known through testing
How is it tested? Differences and precautions for each method
Tests are divided into non-invasive and invasive categories, with different accuracy and uses:
- Urea breath test (carbon-13/carbon-14): Detects 'current active infection' with high accuracy, also commonly used for post-treatment follow-up; stool antigen test also has high sensitivity
- Blood antibody test: Only indicates 'past exposure'; may remain positive after eradication, not suitable for confirming current infection or cure
- Gastric biopsy (invasive): Can perform rapid urease test, histopathology, and bacterial culture (culture can detect antibiotic resistance)
- Note: Recent use of proton pump inhibitors (PPIs), antibiotics, or bismuth can cause false-negative results in breath/stool tests; usually need to discontinue these medications for a period as directed by physician (PPIs about 2 weeks, antibiotics or bismuth about 4 weeks) before testing
Eradication therapy and gastric cancer risk
Eradication refers to using medication to clear the bacteria, a medical treatment prescribed by a physician:
- Standard is combination therapy: PPI plus two or more antibiotics (triple therapy, or bismuth-containing quadruple therapy), course about 10–14 days
- Antibiotic resistance (especially clarithromycin) is a growing concern affecting success rates; therefore, medication must be determined by a physician based on individual conditions and local resistance patterns, and self-medication is not recommended
- Post-treatment follow-up should be done about 4 weeks after completing the course, with PPI discontinued for about 2 weeks as directed, using breath test or stool antigen test (not blood antibody)
- Evidence shows that eradication reduces gastric cancer risk (more significant benefit in high-risk groups); a large-scale eradication program in Matsu, Taiwan reduced prevalence from about 64% to about 15% and gastric cancer incidence by about 50% (Gut, 2021). However, eradication 'reduces' but does not completely eliminate risk
Who needs testing? Neutral recommendations
Whether to test or treat should be determined by the physician based on symptoms and risk assessment:
- Generally agreed candidates for testing: those with current or past peptic ulcer, gastric MALT lymphoma, post-endoscopic resection of early gastric cancer, and those with a family history of gastric cancer (first-degree relative) or residents of high-risk areas
- Whether to screen asymptomatic, average-risk individuals is context-dependent and policy is still evolving—discuss with your physician, and refer to the latest announcements from the Health Promotion Administration on gastric cancer prevention (Taiwan currently targets high-risk groups)
- Reinfection rate after successful eradication in adults is generally low; however, this is a medical decision, and antibiotic misuse can exacerbate resistance—do not self-medicate. This page provides neutral information, not medical advice.
FAQ
Does H. pylori definitely cause gastric cancer?
Not necessarily. It is classified as a Group 1 carcinogen by the WHO IARC and is a major risk factor for gastric cancer; most gastric cancers are associated with it. However, most infected individuals remain asymptomatic for a long time, and infection does not mean cancer will develop. It is a 'modifiable risk factor'; whether testing and treatment are needed should be determined by a physician based on symptoms and risk. This page provides neutral information, not medical advice.
How is H. pylori tested? Which method is accurate?
Common non-invasive tests include the urea breath test (carbon-13/carbon-14) and stool antigen test, which detect current active infection with high accuracy; the breath test is also often used for post-treatment confirmation. Blood antibody tests only indicate 'past exposure' and cannot confirm current infection or cure. Endoscopic biopsy is invasive but allows for pathology and antibiotic susceptibility testing. Recent use of PPIs, antibiotics, or bismuth can cause false negatives; these should be stopped as directed before testing.
Is H. pylori contagious? How is it transmitted?
Yes. Infection usually occurs in childhood, primarily through fecal-oral or oral-oral routes, associated with shared eating, hygiene conditions, and household clustering, so family members often carry it together. In Taiwan, the prevalence among general adults is around 30%, with higher rates in some high-risk areas (per the latest HPA data). Most people are asymptomatic and only know through testing.
How is H. pylori eradicated? Can it recur after eradication?
Eradication involves a prescribed combination therapy: PPI plus two or more antibiotics (triple therapy or bismuth-containing quadruple therapy), typically for 10–14 days. Due to rising antibiotic resistance, the regimen must be determined by a physician—do not self-medicate. About 4 weeks after completion (with PPI stopped for ~2 weeks), a breath or stool antigen test should be done to confirm eradication. Reinfection rates in adults after successful eradication are generally low.
If H. pylori is eradicated, will I not get gastric cancer?
Not exactly. Evidence shows that eradication 'reduces' gastric cancer risk, with greater benefit in high-risk groups—the large-scale eradication program in Matsu, Taiwan, reduced gastric cancer incidence by about 50% (Gut, 2021). However, it reduces rather than eliminates risk; other factors and regular follow-up remain important. Whether to undergo eradication and subsequent follow-up should be discussed with a physician.
If there are no symptoms, should I specifically get tested for Helicobacter pylori?
It depends on individual risk. There is consensus on testing for those with peptic ulcer, gastric MALT lymphoma, post-early gastric cancer resection, or family history of gastric cancer (first-degree relatives), and residents of high-risk areas. For asymptomatic, average-risk individuals, universal screening is still under policy evolution. It is recommended to discuss with a physician and refer to the latest gastric cancer prevention announcements from the Health Promotion Administration (currently targeting high-risk groups in Taiwan).
This page is a neutral compilation of information for reference only, not Medical advice, and does not constitute any diagnostic commitment.